Posted by Michael Wonder on 19 Sep 2022
European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss
19 September 2022 - Phase 3 data that showed people with neovascular or ‘wet’ age-related macular degeneration and diabetic macular oedema treated with Vabysmo up to every four months achieved similar outcomes compared to receiving treatment every two months with aflibercept.
Roche today announced that the European Commission approved Vabysmo (faricimab) for the treatment of neovascular or ‘wet’ age-related macular degeneration and visual impairment due to diabetic macular oedema.
